Joseph Fraietta

Joseph A. Fraietta is a prominent figure in the field of cellular immunotherapy and cancer research. He is an Assistant Professor of Microbiology at the University of Pennsylvania's Perelman School of Medicine and a Co-Founder of DeCART Therapeutics, Inc.13

Academic Background and Research

Dr. Fraietta received his Ph.D. in Microbiology and Immunology from Drexel University College of Medicine in 2012.3 Following his doctoral studies, he completed his postdoctoral training at the University of Pennsylvania's Center for Cellular Immunotherapies under the mentorship of Dr. Carl H. June, a pioneer in CAR T-cell therapy.3

His research focuses on:

• Elucidating the mechanisms of T cell dysfunction in cancer
• Developing next-generation CAR T-cell therapies
• Epigenetic programming of immune cells
• Understanding the requirements for effective memory and effector T cell responses3

Professional Achievements

Dr. Fraietta has made significant contributions to the field of cancer immunotherapy:

• He played a crucial role in developing approaches that led to multiple clinical trials and the FDA approval of the first CAR T-cell therapy.2
• His work has been published in prestigious journals such as Nature, Nature Medicine, and Science Translational Medicine.2
• He received the 2019 National Clinical Research Award from the Clinical Research Forum.2

Role at DeCART Therapeutics

As a Co-Founder of DeCART Therapeutics, Dr. Fraietta is involved in combining Nurix's protein modulation technologies with novel CAR T therapies to improve outcomes for cancer patients.1 The company aims to address current limitations in immunotherapy and enhance the effectiveness of CAR T-cell treatments.1

Dr. Fraietta's expertise in T cell biology and his experience in translating research findings into clinical applications make him a valuable asset to DeCART Therapeutics as they work to develop innovative cancer treatments.